Q2 FY2026 EarningsQ2 FY26 missed consensus estimates on profitability as the company accelerated R&D for its Teverelix program. GAAP Net Loss was $11.68M versus the $5.66M expected, leading to a GAAP EPS of -$0.21 compared to the -$0.13 consensus. Operating expenses surged to $11.48M, significantly exceeding implied cost expectations, primarily driven by a 241% YoY increase in R&D and higher stock-based compensation. While the company secured $22.86M in new debt financing to support its Phase 2 pipeline, the higher-than-expected cash burn and substantial share dilution from ATM/SEPA programs remain key concerns for investors.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Medicus Pharma(MDCX) the EBIT is -11.48 M (-90.8%), Miss estimate;the EPS is -0.21 (+51.16%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B90.80%
-0.01B5.66%
-0.01B96.46%
EPSMiss expectations
-0.2151.16%
-0.1369.77%
-0.080018.61%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf